Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.

@article{Campos2009ExacerbationsIS,
  title={Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy.},
  author={Michael A Campos and Saleh Alazemi and Guoyan Zhang and Adam Wanner and Matthias Salathe and Horst Baier and Robert A Sandhaus},
  journal={Respiratory medicine},
  year={2009},
  volume={103 10},
  pages={1532-9}
}
BACKGROUND The frequency, characteristics and impact of acute exacerbations in patients with alpha-1 antitrypsin deficiency (AATD) and COPD who are on intravenous alpha-1 antitrypsin augmentation therapy have not been described. METHODS 922 subjects with AATD and COPD on augmentation therapy (mean age 54.5 years) were followed with monthly telephone surveys to record exacerbation characteristics, as well as healthcare resource utilization and health-related quality of life (HRQoL… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Exacerbations in {alpha}1-antitrypsin deficiency.

The European respiratory journal • 2005
View 2 Excerpts

Zemaira package insert [updated 2003; cited

L. Aventis Behring
Available from: http://www.fda.gov/cber/products/ zemaira.htm; • 2003
View 1 Excerpt

Similar Papers

Loading similar papers…